November 01, 2013
NIH-funded research shows that differences in the CYP2A6 gene -- which controls in part how fast nicotine is metabolized -- can predict whether nicotine replacement therapies (nicotine lozenge and/or nicotine patch) will be effective in helping a person quit smoking. The effectiveness of buproprion, a non-nicotine based medication often prescribed to quit smoking, was not affected by differences in this gene.
This study adds to previous findings with the CHRNA5 gene, showing that screening for genetic variation may better guide personalized treatments to quit smoking.
For more information, contact the NIDA press office at email@example.com or 301-443-6245.